Jonathan Steckbeck

Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA.

Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA.

Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA.

Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA.

Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA.